6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $106M | -$81M | 0.0% | -87.3% | -$35M | — | $41M |
| 2024 | $76M | -$123M | 0.0% | -179.7% | -$112M | — | $66M |
| 2023 | $76M | -$119M | 0.0% | -181.6% | -$121M | — | $158M |
| 2022 | $412M | $124M | 0.0% | 31.6% | $136M | — | $401M |
| 2021 | $27M | -$212M | 0.0% | -808.2% | -$205M | — | $202M |
| 2020 | $39M | -$181M | 0.0% | -481.3% | -$156M | — | — |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $2M | -$44M | 0.0% | -1956.7% | -$46M | — | $244M |
| Dec '25 | $3M | -$41M | 0.0% | -1755.5% | -$11M | — | $41M |
| Sep '25 | $28M | -$20M | 0.0% | -80.1% | -$32M | — | $65M |
| Jun '25 | $49M | $2M | 0.0% | -1.4% | $12M | — | $98M |
| Mar '25 | $27M | -$23M | 0.0% | -94.5% | -$3M | — | $76M |
| Dec '24 | $31M | -$24M | 0.0% | -71.6% | -$42M | — | $66M |
| Sep '24 | $16M | -$30M | 0.0% | -213.8% | -$7M | — | $122M |
| Jun '24 | $19M | -$38M | 0.0% | -222.9% | -$26M | — | $71M |
| Mar '24 | $10M | -$32M | 0.0% | -376.9% | -$38M | — | $115M |
| Dec '23 | $17M | -$14M | 0.0% | -138.4% | $14M | — | $158M |
| Sep '23 | $17M | -$29M | 0.0% | -201.4% | -$44M | — | $94M |
| Jun '23 | $7M | -$51M | 0.0% | -772.8% | -$7M | — | $142M |
| Mar '23 | $36M | -$24M | 0.0% | -76.7% | -$84M | — | $182M |
| Dec '22 | $402M | $309M | 0.0% | 79.4% | $327M | — | $401M |
| Sep '22 | $3M | -$48M | 0.0% | -1914.0% | -$74M | — | $96M |
| Jun '22 | $5M | -$65M | 0.0% | -1209.5% | -$57M | — | — |
| Mar '22 | $2M | -$73M | 0.0% | -3793.6% | -$60M | — | — |
| Dec '21 | $20M | -$39M | 0.0% | -205.6% | -$55M | — | $202M |
| Sep '21 | $4M | -$61M | 0.0% | -1387.1% | — | — | — |
| Jun '21 | — | -$68M | — | — | — | — | — |
How the market has priced ZYME against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Zymeworks Inc.'s revenue has grown 22.2% per year. These are computed facts, not advice.
As of FY2025, Zymeworks Inc. reported — of total debt against $41M of cash.
In FY2025, gross margin was —, operating margin -87.3%, and net margin -76.6%.
As of Jun '26, Zymeworks Inc. traded at a price-to-earnings ratio of about 6.1× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.